Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CA12 | O43570 | 2/20 | 0.46 |
| ▸ | CA1 | P00915 | 2/20 | 0.46 |
| ▸ | CA9 | Q16790 | 2/20 | 0.46 |
| ▸ | ATR | Q13535 | 1/20 | 0.45 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.45 |
| ▸ | TSHR | P16473 | 1/20 | 0.45 |
| ▸ | CASP1 | P29466 | 1/20 | 0.45 |
| ▸ | ACLY | P53396 | 1/20 | 0.44 |
| ▸ | KDM4E | B2RXH2 | 3/20 | 0.43 |
| ▸ | MAPT | P10636 | 3/20 | 0.43 |
| ▸ | MEN1 | O00255 | 3/20 | 0.43 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.43 |
| ▸ | POLB | P06746 | 2/20 | 0.43 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.43 |
| ▸ | ATM | Q13315 | 1/20 | 0.43 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.43 |
| ▸ | PSMB8 | P28062 | 1/20 | 0.43 |
| ▸ | CYP17A1 | P05093 | 1/20 | 0.42 |
| ▸ | NPC1 | O15118 | 1/20 | 0.42 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30640612 | 0.88 | MAPT (0.54) | CA12CA1CA9SMN1; SMN2KDM4E | |
| SCHEMBL1854623 | 0.88 | MAPT (0.54) | CA12CA1CA9SMN1; SMN2KDM4E | |
| SCHEMBL16412251 | 0.86 | KDM4E (0.49) | CA12CA1CA9KDM4EMAPT | |
| SCHEMBL16303890 | 0.84 | EPHX1 (0.58) | CA12CA1CA9KDM4EMAPT | |
| SCHEMBL10033270 | 0.84 | SMN1; SMN2 (0.50) | SMN1; SMN2TSHRCASP1ACLYKDM4E | |
| SCHEMBL2187189 | 0.84 | KMT2A (0.54) | CA12CA1CA9SMN1; SMN2TSHR | |
| SCHEMBL509152 | 0.84 | CA12 (0.53) | CA12CA1CA9KDM4EMAPT | |
| SCHEMBL30338918 | 0.84 | KMT2A (0.54) | CA12CA1CA9SMN1; SMN2TSHR | |
| SCHEMBL24168682 | 0.83 | ATR (0.44) | CA12CA1CA9ATRMEN1 | |
| SCHEMBL30334730 | 0.83 | ATR (0.44) | CA12CA1CA9ATRMEN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 20 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1966222-A2 | PYRAZOLOTHIAZOLE PROTEIN KINASE MODULATORS | SGX Pharmaceuticals, Inc. (US) | 2008-09-10 | — | — | EP | disclosed |
| US-20070173488-A1 | Pyrazolothiazole Protein Kinase Modulators | SGX PHARMACEUTICALS, INC. (US) | 2007-07-26 | — | — | US | disclosed |
| US-20070173488-A1 | Pyrazolothiazole Protein Kinase Modulators | SGX PHARMACEUTICALS, INC. (US) | 2007-07-26 | — | — | US | disclosed |
| US-20070173488-A1 | Pyrazolothiazole Protein Kinase Modulators | SGX PHARMACEUTICALS, INC. (US) | 2007-07-26 | — | — | US | disclosed |
| WO-2007059341-A2 | PYRAZOLOTHIAZOLE PROTEIN KINASE MODULATORS | SGX PHARMACEUTICALS, INC. (US) | 2007-05-24 | — | — | WO | disclosed |
| WO-2007059341-A2 | PYRAZOLOTHIAZOLE PROTEIN KINASE MODULATORS | SGX PHARMACEUTICALS, INC. (US) | 2007-05-24 | — | — | WO | disclosed |
| CN-1301964-C | Inhibitors of alpha 4-mediated cell adhesion | TANABE SEIYAKU CO (JP) | 2007-02-28 | — | — | CN | disclosed |
| EP-1049662-B1 | INHIBITORS OF ALPHA4 MEDIATED CELL ADHESION | TANABE SEIYAKU CO (JP) | 2006-06-21 | — | — | EP | disclosed |
| US-6855843-B2 | Inhibitors of α4 mediated cell adhesion | TANABE SEIYAKU CO., LTD. (JP) | 2005-02-15 | — | — | US | disclosed |
| US-20030191118-A1 | Inhibitors of alpha4 mediated cell adhesion | TANABE SEIYAKU CO., LTD. | 2003-10-09 | — | — | US | disclosed |
| US-6541477-B2 | Treating inflammation and cardiac conditions with compositions containing acylated piperazine or piperidine rings coupled to phenyl and other aryl groups, such a furan or thiophene | SCIOS, INC. | 2003-04-01 | — | — | US | disclosed |
| US-6521666-B1 | Inhibitors of α4 mediated cell adhesion | TANABE SEIYAKU CO., LTD. (JP) | 2003-02-18 | — | — | US | disclosed |
| US-20020115671-A1 | Inhibitors of p38-a kinase | SCIOS, INC. | 2002-08-22 | — | — | US | disclosed |
| US-6410540-B1 | HEART AND KIDNEY DISEASES; ANTIINFLAMMATORY AGENTS | SCIOS, INC. | 2002-06-25 | — | — | US | disclosed |
| WO-2001064676-A2 | INHIBITORS OF p38-α KINASE | SCIOS, INC. (US) | 2001-09-07 | — | — | WO | disclosed |
| EP-1107758-A2 | USE OF PIPERIDINES AND/OR PIPERAZINES AS INHIBITORS OF P38-ALPHA KINASE | SCIOS INC. (US) | 2001-06-20 | — | — | EP | disclosed |
| CN-1288457-A | Inhibitors of & alpha, 4 mediated cell adhesion | TANABE SEIYAKU CO (JP) | 2001-03-21 | — | — | CN | disclosed |
| EP-1049662-A1 | INHIBITORS OF ALPHA4 MEDIATED CELL ADHESION | TANABE SEIYAKU CO., LTD. (JP) | 2000-11-08 | — | — | EP | disclosed |
| WO-2000012074-A2 | USE OF PIPERIDINES AND/OR PIPERAZINES AS INHIBITORS OF P38-ALPHA KINASE | SCIOS INC. (US) | 2000-03-09 | — | — | WO | disclosed |
| WO-1999036393-A1 | INHIBITORS OF α4 MEDIATED CELL ADHESION | TANABE SEIYAKU CO., LTD. (JP) | 1999-07-22 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030191118-A1 | Inhibitors of alpha4 mediated cell adhesion | ITGB4, ITGA4, VCAM1 | CA12 3199/4885CA1 1768/4885CA9 1948/4885 |
| US-20020115671-A1 | Inhibitors of p38-a kinase | MAPK1, MAP3K1, MAP3K6 | CA12 4725/4885CA1 2028/4885CA9 4311/4885 |
| US-20070173488-A1 | Pyrazolothiazole Protein Kinase Modulators | MAP4K2, MAP4K5, MAP4K3 | CA12 4742/4885CA1 4771/4885CA9 4639/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.